GEN Exclusives

More »

GEN Poll

More »
Apr 09, 2012

Biologic Attrition Rates

Two studies published in recent weeks along with a pair of studies released over the past two years showcase pharma’s drift toward biologic development and provide evidence of the promise of large molecule drugs. In a report dated March 23, the U.K. law firm Withers & Rogers found that by 2009, biologics accounted for 60% of the patents filed by the top 10 pharma companies and that the gap between filings for large and small molecules grew between 2007 and 2009. This positive trend extends beyond innovation to clinical development and final approval, with studies suggesting that biologics hold better prospects than traditional small molecules of advancing all the way from the lab to the clinic to the market. Large molecule success rates in development phases have declined in recent years, however. Considering the tightening of regulatory red tape, what do you think is the future of biologics?

How do you think the rate of success for biologics in clinical development and approval will change in the coming years?

It will increase
 
  57.4%
It will decrease
 
  27.8%
It will remain relatively flat
 
  12.2%
Undecided
 
  2.6%

More Polls » View Results »

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?